BioSpace News Archive

Lucira Health, Inc., a medical technology company, announced both the nationwide launch of its breakthrough Lucira COVID-19 & Flu Home Test in the United States, as well as the combination test’s inclusion in the Australian Register of Therapeutic Goods for use by healthcare professionals in a point-of-care setting.

Biomea Fusion, Inc. today announced initial positive topline data for the first two cohorts of patients with type 2 diabetes mellitus (T2DM) enrolled in the Phase II portion of its ongoing Phase I/II clinical study (COVALENT-111) of BMF-219, the company’s novel, investigational covalent menin inhibitor.

This award honors and confirms PharmaBlock’s commitment to green chemistry and its achievement in developing innovative solutions for sustainable development in the pharmaceutical industry.

Aadi Bioscience, Inc. today provided a corporate update and announced financial results for the fourth quarter and full-year 2022.

The Michael J. Fox Foundation for Parkinson’s Research announced the culmination of the “Ken Griffin Alpha-synuclein Imaging Competition,” a $10-million program launched in 2019 in pursuit of an imaging tracer to visualize the key protein alpha-synuclein in the living brains of people with Parkinson’s disease.

Maravilla LLC, a joint venture between MacuHealth and IOSA, is proud to announce it has acquired the Howard Foundation’s patent portfolio.

CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, names Adel Malek, MD PhD as the company’s Chief Medical Officer.

Codagenix Inc. today announced that Kimber Poffenberger, Ph.D., has been appointed Chief Strategy Officer.

Ratio Therapeutics Inc. (Ratio) today announced the licensing of a Granzyme B-targeted agent for PET imaging applications from Merck, known as MSD outside the United States and Canada.

Mission Bio has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT), leveraging its Tapestri® Platform to improve analytical assays and cell manufacturing processes.